论文部分内容阅读
目的:研究抑癌基因PTEN在原发性食管鳞状细胞癌(ESCC)组织中的表达及临床意义。方法:应用免疫组化SP法检测68例ESCC标本及相应癌旁组织中PTEN蛋白的表达情况,并分析与各临床病理因素和患者生存率的关系。结果:PTEN蛋白在ESCC组织中的阳性表达率为58.8%,显著低于癌旁组织95.0%;PTEN在组织学分级为Ⅱ/Ⅲ级的ESCC组织中表达率(51.0%)显著低于Ⅰ级(78.9%);在临床TNM分期为Ⅱ/Ⅲ期病例中的表达率(28.6%)显著低于Ⅰ期患者(80.0%);有淋巴结转移组的表达率(33.3%)显著低于无淋巴结转移组(75.6%);3年随访生存组患者的PTEN表达率(82.1%)显著高于死亡组患者(42.5%),各组差异均有统计学意义,P<0.05。结论:抑癌基因PTEN在ESCC的发生发展过程中表达下调,可做为评价ES-CC患者预后的有用参考指标。
Objective: To study the expression and clinical significance of tumor suppressor gene PTEN in primary esophageal squamous cell carcinoma (ESCC). Methods: Immunohistochemical SP method was used to detect the expression of PTEN protein in 68 specimens of ESCC and its corresponding adjacent tissues, and analyze the relationship with clinical pathological factors and survival rate. RESULTS: The positive expression rate of PTEN protein in ESCC tissues was 58.8%, which was significantly lower than that in paracancerous tissues (95.0%). The expression rate of PTEN in ESCC tissues with grade II/III histological grade (51.0%) was significantly lower than that of grade I. (78.9%); The expression rate in clinical TNM stage II/III cases (28.6%) was significantly lower than that in stage I patients (80.0%); the rate of lymph node metastasis group (33.3%) was significantly lower than that without lymph nodes In the metastatic group (75.6%), the expression rate of PTEN was significantly higher in the survival group (82.1%) than in the death group (42.5%) in the 3-year follow-up group, and there was a significant difference between the groups (P<0.05). Conclusion: The down-regulation of tumor suppressor gene PTEN during the development of ESCC can be used as a useful index to evaluate the prognosis of ES-CC patients.